Kreatech to supply DNA FISH probes for U.S. lung study, 7/13:109

Kreatech has signed an agreement with the Lung Cancer Mutation Consortium (LCMC) allowing LCMC study sites to use Kreatech’s Repeat-Free Poseidon fluorescent in situ hybridization (FISH) probes to help identify molecular (DNA) changes in study samples.

The LCMC represents the largest initiative in the United States to prospectively examine nonsmall cell lung cancer tumors for molecular changes that have been linked with patient response to available therapies. The LCMC is providing critical genetic information on the biological profile of each patient’s tumor to allow patients to join clinical trials directed at their particular tumor profile.

Kreatech will supply its DNA FISH probes to participating LCMC labs for testing genetic aberrations of ROS1, RET, ALK, and MET in the study. Kreatech will also provide technical support for the evaluation, validation, and clinical trial testing of the probes used in LCMC participating labs.

Kreatech, 919-407-83470